[Antibacterial activity in vitro and in vivo of the trimethoprim-sulphamethoxazole combination].
D000818:Animals; D000900:Anti-Bacterial Agents / Q000494:pharmacology*; D004338:Drug Combinations; D004352:Drug Resistance, Microbial; D004926:Escherichia coli / Q000187:drug effects; D005493:Folic Acid Antagonists / Q000494:pharmacology*; D007710:Klebsiella Infections / Q000188:drug therapy; D007711:Klebsiella pneumoniae / Q000187:drug effects; D008297:Male; D051379:Mice; D008826:Microbial Sensitivity Tests; D011511:Proteus / Q000187:drug effects; D011550:Pseudomonas aeruginosa / Q000187:drug effects; D011743:Pyrimidines / Q000494:pharmacology*; D012475:Salmonella / Q000187:drug effects; D012760:Shigella / Q000187:drug effects; D013203:Staphylococcal Infections / Q000188:drug therapy; D013210:Staphylococcus / Q000187:drug effects; D013290:Streptococcal Infections / Q000188:drug therapy; D013291:Streptococcus / Q000187:drug effects; D013420:Sulfamethoxazole / Q000494:pharmacology* / Q000627:therapeutic use; D014295:Trimethoprim / Q000494:pharmacology / Q000627:therapeutic use
D000900:Anti-Bacterial Agents; D004338:Drug Combinations; D005493:Folic Acid Antagonists; D011743:Pyrimidines; D014295:Trimethoprim; D013420:Sulfamethoxazole